Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (181)	6/12/2001 7:13:26 AM
From: nigel bates	Read Replies (1) \| Respond to of 1022

Not the big deal that validates, but still... SAN DIEGO, June 12 /PRNewswire/ -- Xenerex Biosciences, a subsidiary of AVANIR Pharmaceuticals (Amex: AVN - news), and Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM - news) today announced that they have entered into an antibody research collaboration agreement. The collaboration is designed to discover, develop and potentially commercialize fully human monoclonal antibody therapies for the treatment of solid tumor cancers. Terms of the agreement provide for the transfer of three antigen targets from Peregrine to Xenerex for the subsequent generation of fully human monoclonal antibodies, utilizing Xenerex's antibody generation technology. Xenerex will receive upfront research fees and could receive milestones and royalties on future product sales. Peregrine will be responsible for product development, manufacturing and commercialization of any products developed through the collaboration. The specific financial terms of the agreement were not disclosed. ``Our opportunity to work with Peregrine is yet another step forward in validating the unique technology that Xenerex offers to the biopharmaceutical marketplace,'' said J. David Hansen, president and chief operating officer of Xenerex Biosciences. ``In partnering with Peregrine, we are expanding the number and types of proteins to which we can apply our antibody generation capabilities. Additionally, we are implementing our strategy of continuing to build our client base with partners also focused on novel treatments and technologies.'' ``We look forward to working with Xenerex for the generation of antibodies against several targets we have identified as being promising for our therapeutic antibody programs,'' said Steven King, Peregrine's Vice President of Technology and Product Development. ``Based on the strength of data from pre-clinical animal studies using murine antibodies against several different targets, we felt it was time to begin development of fully human antibodies that could potentially serve as candidates for clinical studies. We believe that Xenerex has the ability to efficiently generate these human antibodies. Based on data from our animal models, we feel that these antibodies have the potential to be used as unconjugated antibodies for the treatment of a variety of different solid tumors.'' Peregrine Pharmaceuticals is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its ``collateral targeting technologies''. These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The company has three collateral targeting technologies: Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The company's lead TNT based drug, Cotara(TM), is currently being studied in the U.S. in a Phase II trial for brain cancer and five Phase I trials for colorectal, pancreatic, biliary, sarcoma and liver cancers. The company also has a direct tumor-targeting agent called Oncolym® for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym is being studied in a U.S. Phase I/II...